Anemia in children with chronic kidney disease

Area of Science:

• Pediatric Nephrology
• Hematology
• Internal Medicine

Background:

• Anemia is a frequent complication in children with chronic kidney disease (CKD).
• It results from multifactorial causes including erythropoietin deficiency, iron deficiency, and inflammation.
• Anemia in pediatric CKD is associated with adverse outcomes like increased mortality and left ventricular hypertrophy.

Purpose of the Study:

• To review the causes and consequences of anemia in pediatric CKD.
• To discuss current and emerging treatment options for anemia in this population.
• To highlight the role of iron management in conjunction with erythropoiesis-stimulating agents.

Main Methods:

• Literature review of studies on anemia in pediatric chronic kidney disease.
• Analysis of treatment efficacy for recombinant human erythropoietin, darbepoetin alfa, and iron supplementation.
• Evaluation of oral versus intravenous iron administration routes.

Main Results:

• Erythropoiesis-stimulating agents (ESAs) like recombinant human erythropoietin and darbepoetin alfa are effective in managing anemia.
• Darbepoetin alfa offers the advantage of less frequent administration.
• Iron deficiency is a critical factor, often requiring intravenous iron, especially in hemodialysis patients, for optimal response to ESAs.

Conclusions:

• Anemia in pediatric CKD is a significant clinical issue requiring comprehensive management.
• Treatment involves addressing underlying causes, utilizing ESAs, and ensuring adequate iron status.
• Intravenous iron administration is a key strategy for refractory anemia in pediatric CKD patients, particularly those on dialysis.